An observational study in Coronary Arterial Disease (CAD), sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by University of Sao Paulo General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Atherosclerosis with a site in Brazil — 8 open to participants now, 15 under way, 10 of them phase 3. Atherosclerosis · Brazil.
Among the 54 studies in Atherosclerosis with a site in Brazil, this one is one of 5 that started in 2024, is one of 8 observational ones, reaches primary completion later than 0 of the 14 other live ones, and was the 47th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →8 of the 54 studies in Atherosclerosis with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 25 more countries
Ages 18+
Hospital do Coracao · Sites in Brazil
Ages 45+
AstraZeneca · Sites in Brazil, United States, Argentina and 33 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Brazil, Argentina
Ages 18–100
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 40–70 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 19 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is below the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 203 across the 45 interventional studies, 143 across the 8 observational. Of the 31 that completed or were terminated, 10 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
University of Sao Paulo General Hospital has 8 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Atherosclerosis with a site in Brazil that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Atherosclerosis with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The presence and clinical evolution of coronary atherosclerosis depend on various classic risk factors and biomarkers. However, the search for more specific markers is necessary, especially for individuals with non-obstructive coronary artery disease, lesions \< 50%. In this regard, the field of plasma proteomics could enable the discovery of these novel biological indicators. To evaluate and compare the differences in the proteomic profile among three groups of individuals, namely those without atherosclerotic lesions, those with non-obstructive lesions in coronary flow (\< 50%), and those with obstructive lesions (e 50%), as determined by findings from coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA). The aim is to assess their relationship with typical clinical events of coronary artery disease (CAD) and detect potential prognostic biomarkers associated with each group. A cross-sectional cohort study involving 66 patients selected and recruited based on CCTA and ICA results obtained at the Heart Institute of the Hospital das Clínicas of the School of Medicine, University of São Paulo (InCor, HC-FMUSP). The patients were divided into the aforementioned three groups, with 22 individuals in each group, and underwent blood collection for biochemical and proteomic analysis, as well as clinical and demographic characterization. The likely differentiation of the proteomic and metabolomic profile among the groups and identification of biological markers for CAD would contribute to the understanding of its pathophysiology and enable a change in clinical decision-making, particularly regarding disease progression prevention and clinical events.
INTRODUCTION The presence and clinical evolution of coronary atherosclerosis depend on several classic risk factors, such as age, sex, arterial hypertension, dyslipidemia, diabetes, smoking, family history, and others, including inflammatory markers, coronary calcium, genetic scores, ethnicity, and lifestyle.
However, the markers for disease progression in individual patients remain uncertain; what is currently available is the average progression, not the certainty of real, personalized evolution. This is especially true in individuals with non-obstructive lesions (\<50%). Nevertheless, such patients frequently suffer coronary events, such as myocardial infarction and acute coronary syndrome. Moreover, they represent a large proportion of individuals who experience cardiovascular events.
Thus, the search for more specific prognostic biomarkers continues. The field of plasma proteomics offers a great opportunity for discovering these new markers. Specifically, chemical compounds related to inflammation, platelet function, or endothelial dysfunction may have distinct expression patterns in the aforementioned patients.
With the early detection of coronary artery disease (CAD), ideal and personalized therapies can be initiated. Metabolites can clarify pathogenicity and potential therapeutic targets. A combination of multiple small-molecule metabolites may provide excellent diagnostic value. Therefore, metabolomics, a rapidly expanding field in systems biology, can indicate metabolic alterations in response to disease progression.
For this purpose, plasma, often considered a pool of metabolites, has been an excellent source for determining the metabolic profile in certain diseases. This has also been demonstrated in Coronary Artery Disease (CAD).
Fan et al., in a Chinese cohort, showed statistically significant differences in the metabolism of glycerophospholipids, linoleic acid, purines, and sphingolipids between normal individuals and those with non-obstructive disease. Furthermore, sphingolipids, glycerophospholipids, valine, leucine, isoleucine, primary bile acid biosynthesis, and arginine and proline metabolism differed between obstructive and non-obstructive coronary disease. These differences were detected in 89 differential metabolites.
In the African-American cohort of the Jackson Heart Study, N-acylamides, leucine, and lipid species were associated with the incidence of coronary artery disease.
OBJECTIVE Therefore, the objective of this study is to evaluate differences in the plasma proteomic profile among three groups: Group I, without atherosclerotic lesions; Group II, with non-obstructive lesions (\<50%); and Group III, with obstructive lesions (≥50%), based on findings from coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA), in order to assess their relationship with typical clinical events of coronary artery disease (CAD) and identify potential biomarkers associated with the prognosis of each group.
Thus, in this pilot project, we hypothesize that plasma proteomic and metabolomic profiles may differ among these three patient groups.
METHODS This is a cross-sectional cohort study with 66 patients from the Heart Institute (InCor) of the Hospital das Clínicas, Faculty of Medicine, University of São Paulo (HC-FMUSP). Patients were selected based on coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA) performed at InCor HC-FMUSP between 2011 and 2017 and divided into three groups: Group I (n = 22), without atherosclerotic lesions; Group II (n = 22), with non-obstructive lesions (\<50%); and Group III (n = 22), with obstructive lesions (≥50%). Patients will be randomly recruited from the Brazilian Cohort Project on Non-Obstructive Coronary Disease: Lesions with Less Than 50% Obstruction - BARD. This project was previously approved by the Ethics Committee.
Patients will be invited to participate in the study after a selection process based on medical records from the atherosclerosis and chronic coronary disease outpatient clinics at InCor. During a single visit, they will receive detailed information about the study. Upon their agreement and signing of the informed consent form (ICF), they will be included in the study and undergo blood collection and demographic data assessment on the same day.Participation in the study involves risks related to blood collection and the confidentiality of their information. Access to the data will be restricted to study personnel, who are professionally committed to maintaining absolute confidentiality. Participants' names will be replaced by a code, and the data collected for the study will not contain any elements that could potentially allow personal identification.
For sample size calculation, two approaches will be used: the proportion of significant bins-predefined segments in the spectrum after processing metabolomic fingerprinting data-(untargeted analysis) or the proportion of significant proteins (targeted analysis). It is expected that these proportions will be statistically significant, which generally does not exceed 50%. Since this is a pilot project, and there is no prior knowledge of the proportion of significant proteins, Probabilistic Principal Component Analysis (PPCA) was chosen, meaning that an untargeted analysis approach was applied.
For this choice, the following numerical covariates were determined: age, blood glucose, HDL-cholesterol, LDL-cholesterol, total cholesterol, and triglycerides; and categorical covariates: coronary lesion (obstructive lesion, non-obstructive lesion, and no lesion), diabetes mellitus (DM), dyslipidemia (DLP), systemic arterial hypertension (SAH), and smoking. The false discovery rate (FDR) was set at 5%, bins at 200, and the proportion of significant differences at 20%. Thus, the sample size calculated using MetSizeR software version 2.0 was 22 individuals per group (total of 66 participants). The study variables will be presented using descriptive statistics according to variable type (qualitative or quantitative). For qualitative variables, frequencies and percentages will be calculated. For quantitative variables, mean, median, standard deviation, minimum, maximum, first quartile, and third quartile will be presented.
The comparison between two dependent measures will be performed using the non-parametric Wilcoxon test. For comparisons between independent groups, the non-parametric Mann-Whitney test will be used.
The significance level adopted for all hypothesis tests will be 5%. Analyses will be performed using SPSS v.25 for Windows ©.
PROTOCOL During the participant's visit, after obtaining informed consent, demographic characteristics will be recorded (age, sex, risk factors, blood pressure, heart rate, weight, and height), and blood samples will be collected for laboratory biochemical analysis (fasting blood glucose, glycated hemoglobin, troponin I, complete blood count, urea, creatinine, sodium, potassium, high-sensitivity C-reactive protein (hs-CRP), aspartate transaminase, alanine transaminase, total and fractionated bilirubin, alkaline phosphatase, gamma-glutamyl transferase, prothrombin time, total cholesterol and fractions, and triglycerides) and proteomic analysis. The biochemical profile will be analyzed at the Clinical Analysis Laboratory of InCor. Blood samples for the proteomic profile will be collected in standard tubes, coagulated at 4°C for 1 to 2 hours, then warmed to room temperature for 30 minutes before centrifugation (2500g/10 min). The plasma will be stored at -80°C in the freezer of the Vascular Biology Laboratory on the 9th floor of InCor and later sent in a single batch to the Neuroproteomics Laboratory at UNICAMP for analysis. Additionally, metabolomic analysis will be conducted at the Max Feffer Laboratory of Plant Genetics, Department of Genetics, "Luiz de Queiroz" College of Agriculture (ESALQ), University of São Paulo, Piracicaba. Plasma samples will be depleted of the most abundant proteins, and the low-abundance protein fraction will be digested with trypsin. The resulting peptides will then undergo liquid chromatography coupled with mass spectrometry (LC-MS) for proteomic and metabolomic analyses.
DATA ANALYSIS The data obtained by LC-MS will be processed using algorithms for protein identification and quantification, with searches conducted in databases such as the Uniprot Human Proteomic Database (http://www.uniprot.org/). For spectrum processing, the software Progenesis QI for Proteomics 4.0 will be used. The data generated will serve as the basis for protein identification and quantification using the label-free MSE method. In the software, samples will be categorized into the predefined study groups. Proteins will be identified using strict search parameters, requiring at least two unique peptides for protein identification. Differentially expressed proteins between groups will be considered based on a fold change cutoff of 1.5, for both upregulated and downregulated expression. The confidence score will be set at ≥3, and analysis of variance (ANOVA) will be conducted with a p-value threshold of ≤0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No atherosclerotic lesions
Non-obstructive coronary lesions (\< 50%)
Obstructive coronary lesions (≥ 50%)
Identification of Differentially Expressed Proteins in Coronary Artery Disease Groups
Identification of Differentially Expressed Proteins Among Three Groups (No Lesion, Non-Obstructive Lesion, and Obstructive Lesion)
Time frame: 1 Year
Proteomic Biomarkers and Classic Risk Factors Correlation
Correlation between proteomic biomarkers and classic risk factors
Time frame: 1 Year
Association of Identified Proteins with Clinical Events in CAD
Association of identified proteins with typical clinical events of coronary artery disease
Time frame: 1 Year
Differential Protein Expression in Relation to Laboratory Biochemical Parameters
Analysis of differential protein expression in relation to laboratory biochemical parameters.
Time frame: 1 Year
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo General Hospital →